 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab |
(Hospital Universitario Ramón y Cajal (Madrid)) (Hospital Universitario Ramón y Cajal (Madrid)) (Institut d'Investigació Biomèdica de Girona) (Hospital Universitario Ramón y Cajal (Madrid)) (Hospital Universitario Ramón y Cajal (Madrid)) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (Institut d'Investigació Biomèdica de Girona) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (Hospital Clínico San Carlos (Madrid)) (Hospital Universitario Ramón y Cajal (Madrid)) (Hospital Universitario Ramón y Cajal (Madrid)) (Hospital Universitario Ramón y Cajal (Madrid))| Data: | 2021 |
| Resum: | UDHEBRON. |
| Resum: | To explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment. Multicenter prospective study including 57 RRMS patients treated with alemtuzumab followed for 3. 25 [3. 5-4. 21] years, (median [interquartile range]). Blood samples were collected at baseline, and leukocyte subsets determined by flow cytometry. We had additional samples one year after the first cycle of alemtuzumab treatment in 39 cases. Twenty-two patients (38. 6%) developed AIAEs during follow-up. They had higher B-cell percentages at baseline (p=0. 0014), being differences mainly due to plasmablasts/plasma cells (PB/PC, p=0. 0011). Those with no AIAEs had higher percentages of CD4+ T cells (p=0. 013), mainly due to terminally differentiated (TD) (p=0. 034) and effector memory (EM) (p=0. 031) phenotypes. AIAEs- patients also showed higher values of TNF-alpha-producing CD8+ T cells (p=0. 029). The percentage of PB/PC was the best variable to differentiate both groups of patients. Baseline values >0. 10% closely associated with higher AIAE risk (Odds ratio [OR]: 5. 91, 95% CI: 1. 83-19. 10, p=0. 004). When excluding the 12 patients with natalizumab, which decreases blood PB/PC percentages, being the last treatment before alemtuzumab, baseline PB/PC >0. 1% even predicted more accurately the risk of AIAEs (OR: 11. 67, 95% CI: 2. 62-51. 89, p=0. 0007). The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0. 0058). A PB/PC percentage <0. 1% at baseline identifies MS patients at low risk of secondary autoimmunity during alemtuzumab treatment. . |
| Ajuts: | Ministerio de Economía y Competitividad RD16/0015/0001 Ministerio de Economía y Competitividad RD16/0015/0004 Ministerio de Economía y Competitividad RD16/0015/0006 Ministerio de Economía y Competitividad RD16/0015/0013 Instituto de Salud Carlos III PI18/00572 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | Multiple sclerosis ; Side effects ; Autoimmunity ; Disease modifying treatments ; Alemtuzumab ; Biomarkers ; B cells |
| Publicat a: | Frontiers in immunology, Vol. 12 (october 2021) , ISSN 1664-3224 |
